Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

Literature DB >> 29424089

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

A T Layton¹, V Vallon^2,3.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 29424089 PMCID： PMC5867254 DOI： 10.1111/apha.13050

Source DB: PubMed Journal: Acta Physiol (Oxf) ISSN： 1748-1708 Impact factor: 6.311

× No keyword cloud information.

8 in total

1. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.

Authors: Julie O'Neill; Angelica Fasching; Liselotte Pihl; Daniela Patinha; Stephanie Franzén; Fredrik Palm
Journal: Am J Physiol Renal Physiol Date: 2015-06-03

2. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.

Authors: Anita T Layton; Volker Vallon
Journal: Am J Physiol Renal Physiol Date: 2018-01-17

Review 3. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Authors: Volker Vallon; Scott C Thomson
Journal: Diabetologia Date: 2016-11-22 Impact factor: 10.122

4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245

5. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245

6. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Authors: Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink
Journal: Clin J Am Soc Nephrol Date: 2017-03-16 Impact factor: 8.237

7. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Authors: Christoph Wanner; John M Lachin; Silvio E Inzucchi; David Fitchett; Michaela Mattheus; Jyothis George; Hans J Woerle; Uli C Broedl; Maximilian von Eynatten; Bernard Zinman
Journal: Circulation Date: 2017-09-13 Impact factor: 29.690

8. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245

8 in total

7 in total

1. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.

Authors: Anita T Layton; Volker Vallon
Journal: Am J Physiol Renal Physiol Date: 2018-01-17

2. Recent advances in renal epithelial transport.

Authors: Anita T Layton
Journal: Am J Physiol Renal Physiol Date: 2018-12-05

3. Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney.

Authors: Hiddo J L Heerspink
Journal: Nephrol Dial Transplant Date: 2019-12-01 Impact factor: 5.992

4. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.

Authors: Mehrshad Sadria; Anita T Layton
Journal: PLoS Comput Biol Date: 2020-10-08 Impact factor: 4.475